Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of VVYP peptide or salt thereof in preparing medicine for preventing or treating non-alcoholic fatty liver disease
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A fatty liver disease, non-alcoholic technique for use in medicine
Inactive Publication Date: 2018-11-06
JIANGXI HERBFINE HI TECH +1
View PDF6 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, there is no record about the effect of Val-Val-Tyr-Pro peptide on the prevention and treatment of non-alcoholic fatty liver disease in the prior art
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0026] Example 1: Protective effect of Val-Val-Tyr-Pro peptide on fatty acid-induced HepG-2 cell injury
[0027] In this example, the protective effect of Val-Val-Tyr-Pro peptide on hepatic steatosis and inflammatory injury in the occurrence and development of NASH was studied through fatty acid induction experiments performed on HepG-2 cells in vitro.
[0028] 1. Experimental materials
[0029] 1.1 Cells: HepG-2 cells, purchased from the US ATCC cellbank.
[0033] Select the HepG-2 cell seeding plate, plant a 96-well plate, and the number of cells is 10,000 / well (100 μL). The following groups were set up on the plate: 1) blank group; 2) model group (oleic acid and palmitic acid were prepared at a ratio of 1:2, the concentratio...
[0042] In this example, by establishing a non-alcoholic steatohepatitis (NASH) mouse model, the intervention effect of Val-Val-Tyr-Pro peptide on liver steatosis and inflammatory injury in the occurrence and development of NASH was studied.
[0045] 1.2 Test drug: Val-Val-Tyr-Pro peptide acetate sample
[0046] 1.3 Equipment and reagents: analytical balance, automatic biochemical analyzer
[0047] 2. Experimental method
[0048] By feeding C57BL / 6 mice with a methioninecholine-deficient (MCD) diet for 2 weeks, a non-alcoholic steatohepatitis ((NASH) mouse model was established. Val-Val-Tyr-Pro peptide low (2mg / kg) and high (8mg / kg) dose groups. Collect serum and liver tissue samples from the model group, intervention group and control g...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention relates to the technical field of medicines, in particular to application of VVYP peptide or salt thereof in preparing medicine for preventing or treating a non-alcoholic fatty liverdisease, and the amino acid sequence of the VVYP peptide is Val-Val-Tyr-Pro. The invention further provides a pharmaceutical composition containing therapeutically effective amount of VVYP peptide and the salt thereof and one or multiple excipients, and the composition can be prepared into an oral preparation and contains the peptide with the therapeutically effective amount being 10-50 mg and the salt thereof. The Val-Val-Tyr-Pro peptide is obviously superior to bicyclol in the aspects of protecting liver mitochondria and lowering lipid. A new clinical method is provided for treating and preventing the non-alcoholic fatty liverdisease, and the potential medical field of the VVYP peptide is broadened.
Description
technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to the application of VVYP peptide or its salt in the preparation of drugs for preventing or treating non-alcoholic fatty liverdisease. Background technique [0002] Non-alcoholic fatty liver disease is one of the important chronic liver diseases that endanger human health, and its incidence is increasing day by day. The current incidence in the world is about 20%. Non-alcoholic fatty liver disease itself can affect the progression of other chronic liver diseases, and it is mutually causal with the onset of metabolic syndrome. Since its pathogenesis is still unclear, there is a lack of effective control measures. [0003] Val-Val-Tyr-Pro peptide (i.e. VVYP, wherein, Y stands for: L-tyrosine; V stands for: L-valine; P stands for: L-proline) has many patent documents in Japan Report: Val-Val-Tyr-Pro peptide has the effect of inhibiting the concentration of triglyceride ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More